(19)

(11)

EP 4 529 467 A2

(12)

(88) Date of publication A3: 07.03.2024 (43) Date of publication: 02.04.2025 Bulletin 2025/14 (21) Application number: 23812729.4 (22) Date of filing: 23.05.2023

(51) International Patent Classification (IPC):  A61K 39/395(2006.01) A61P 11/00(2006.01) C07K 16/28(2006.01) A61P 31/14(2006.01) (52) Cooperative Patent Classification (CPC): A61K 9/0078; C07K 16/1003; C07K 2317/41; A61K 2039/505; A61K 2039/543; A61K 2039/544 (86) International application number: PCT/US2023/067373 (87) International publication number: WO 2023/230486 (30.11.2023 Gazette 2023/48)

(84) Designated Contracting States: AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC ME MK MT NL NO PL PT RO RS SE SI SK SM TR Designated Extension States: BA Designated Validation States: KH MA MD TN (30) Priority: 23.05.2022 US 202263345019 P 16.08.2022 US 202217889141 (71) Applicants: Inhalon Biopharma, Inc. Morrisville, NC 27560 (US) The University of North Carolina at Chapel Hill Chapel Hill, NC 27514 (US)

(72) Inventors: LAI, Samuel K. Chapel Hill, North Carolina 27514 (US) MOENCH, Thomas R. Morrisville, North Carolina 27560 (US) HUTCHINS, Jeff T. Morrisville, North Carolina 27560 (US) (74) Representative: Hancox, Jonathan Christopher et al Venner Shipley LLP Windsor House 6-10 Mount Ephraim Road Tunbridge Wells, Kent TN1 1EE Tunbridge Wells, Kent TN1 1EE (GB)